Project CodeMRC25IIARCa McLarenTitleT cell immune modulation during severe bacterial infectionResearch ThemeInfection, Immunity, Antimicrobial Resitance and RepairSummaryThere is no licenced vaccine against Staphylococcus aureus which produces life-threatening bloodstream infections ("bacteraemia") ar has evolved antibiotic-resistant strains. However, mucosal-associate invariant T (MAIT) cells can combat certain antibiotic-resistant bacter positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia.DescriptionSignificance:Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strains	d eria, e
Research ThemeInfection, Immunity, Antimicrobial Resitance and RepairSummaryThere is no licenced vaccine against Staphylococcus aureus which produces life-threatening bloodstream infections ("bacteraemia") ar has evolved antibiotic-resistant strains. However, mucosal-associate invariant T (MAIT) cells can combat certain antibiotic-resistant bacter positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia.DescriptionSignificance:Staphylococcus aureus (S. aureus) is a Gram-positive 	d eria, e
SummaryThere is no licenced vaccine against Staphylococcus aureus which produces life-threatening bloodstream infections ("bacteraemia") ar has evolved antibiotic-resistant strains. However, mucosal-associate invariant T (MAIT) cells can combat certain antibiotic-resistant bacter positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia.DescriptionSignificance: 	d eria, e
produces life-threatening bloodstream infections ("bacteraemia") ar has evolved antibiotic-resistant strains. However, mucosal-associate invariant T (MAIT) cells can combat certain antibiotic-resistant bacter positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia.DescriptionSignificance: Staphylococcus aureus (S. aureus) is a Gram-positive 	d eria, e
has evolved antibiotic-resistant strains. However, mucosal-associate invariant T (MAIT) cells can combat certain antibiotic-resistant bacter positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia. Description Significance: Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	d eria, e
 invariant T (MAIT) cells can combat certain antibiotic-resistant bacter positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia. Description Significance: Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strained in the use of the section of the section of the section of the section of the targets is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there in the UK (52,000 deaths/year). These numbers are worrying as there in the targets of the targets of the targets and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained to sepsis which is the primary cause and since antibiotic-resistant strained tot sepsis which is the primary cause and since antibiotic-res	eria,
positioning them as ideal targets for new vaccines. The student will examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia.DescriptionSignificance: Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strain	2
examine how MAIT cell responses against Staphylococcus aureus are affected by the bacterium during bacteraemia.DescriptionSignificance: Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strain	
affected by the bacterium during bacteraemia.DescriptionSignificance: Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
Description Significance: Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
bacterium that can produce severe infections of the human body, including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can b to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
including the bloodstream where it is most lethal (15-50% mortality rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can let to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
rates). Bloodstream infections ("bacteraemia"), caused by S. aureus Escherichia coli, affect >50,000 people in the UK each year and can be to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	ĺ
Escherichia coli, affect >50,000 people in the UK each year and can le to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
to sepsis which is the primary cause of death in hospitalised patients the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
the UK (52,000 deaths/year). These numbers are worrying as there i licenced vaccine against S. aureus and since antibiotic-resistant strai	
licenced vaccine against S. aureus and since antibiotic-resistant strai	
such as MRSA, pose a serious threat to global public health. T cells a	re
immune cells that are important for successful vaccination and	
protective immunity from infection. "Innate-like" T cells, such as	
mucosal-associated invariant T (MAIT) cells, can mediate rapid,	
protective immunity against bacteria and can combat certain antibio	TIC-
resistant strains. Patients with sepsis and severe COVID-19 display	
reduced levels of circulating MAIT cells, implicating their importance	
preventing severe infections and identifying them as ideal targets fo new vaccines or immunotherapies. However, our knowledge of the	
of MAIT cells in the immunopathology of S. aureus bacteraemia is	ole
unclear and whether MAIT cell alterations are predictive of poor	
outcome. Originality: S. aureus can be targeted by cytotoxic MAIT	
cells, yet our knowledge of the mechanisms involved, especially at the	
level of individual T cell receptor (TCR) "clonotypes" is poor. As a	
countermeasure, S. aureus produces toxins, such as "superantigens'	,
that specifically target and weaken or kill T cells. Superantigens (SAg	
drive life-threatening complications of infection, such as toxic shock	-
syndrome and bacteraemia, and act to excessively stimulate T cells a	
render them unresponsive and dysfunctional. There is evidence that	
MAIT cells are innately more sensitive to the immune evasive action	
SAgs than more conventional types. However, the reasons why are	-
unclear. Research Question: Are MAIT cell responses to S. aureus	
dominated by specific clonotypes that become depleted or poorly	
functional during bacteraemia in humans and are also highly sensitiv	ve to
SAg-mediated evasion? Objectives: The student will combine	
immunological, molecular and sequencing-based techniques to gain	a
comprehensive understanding of how MAIT cells respond to S. aure	
the clonotypic level, how these protective immune responses are	
impacted during S. aureus bacteraemia in human patients and the	
mechanisms SAgs use to target MAIT cells. The specific aims are: -	Aim
1: To define the MAIT cell clonotypic response to S. aureus Aim 2:	
dissect the mechanism of SAg-driven immune evasion of MAIT cells	

	Aim 3: To profile MAIT cell responses in patients with S. aureus bacteraemia Research Training: The student will receive expert training in immunological (cell culture, flow cytometry, ELISA), molecular (lentiviral transduction) and sequencing (TCR clonotyping) techniques. They will also gain experience in using systems-based approaches for integrating clinical information with biological datasets. The project has been designed with flexibility to enable the student to steer the project and align it with their interests. Added-value: The student will work across disciplinary boundaries, by combining biological and mathematical approaches, and will benefit from established local and international collaborations in Cardiff, Bristol and Australia. Knowledge transfer and impact: The student will publicise their research to a specialist audience through peer-reviewed publications and presentations at institutional seminars, research days and scientific meetings or conferences. Outreach to lay audiences will be performed using social media, institute websites and engagement opportunities arranged under guidance from Prof Eberl (Academic Lead for Public Involvement and Engagement).	
Supervisory Team		
Lead Supervisor	Dr. Jamas Malavan	
Name	Dr James McLaren	
Affiliation	Cardiff	
College/Faculty	College of Biomedical and Life Sciences	
Department/School	School of Medicine	
Email Address	mclarenje@cardiff.ac.uk	
Co-Supervisor 1		
Name	Professor Matthias Eberl	
Affiliation	Cardiff	
College/Faculty	College of Biomedical and Life Sciences	
Department/School	School of Medicine	
Co-Supervisor 2		
Name	Dr Jonathan Underwood	
Affiliation	Cardiff	
College/Faculty	College of Biomedical and Life Sciences	
Department/School	School of Medicine	
Co-Supervisor 3		
Name	Professor Linda Wooldridge	
Affiliation	Bristol	
College/Faculty		
Department/School		